Cadrenal Therapeutics, Inc. - Common Stock —— 季度资产负债表 (NASDAQ:CVKD) | MetaTrader

展开完整图表完整图表

新闻

Cadrenal schedules FDA meeting for HIT drug CAD-1005

Cadrenal Therapeutics股价因二期临床试验结果大涨

Cadrenal Therapeutics stock surges on Phase 2 trial results

Cadrenal的CAD-1005在HIT试验中显示血栓减少

Cadrenal’s CAD-1005 shows reduction in blood clots in HIT trial

Cadrenal强调12-LOX抑制剂对血液疾病的潜力

Cadrenal highlights potential of 12-LOX inhibitor for blood disorder

Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox

Cadrenal Therapeutics appoints PTC Therapeutics CMO to board

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics首席财务官Szot出售价值1496美元股票